Background/Aims: Frail patients with chronic kidney disease (CKD) have an increased hospitalisation and mortality rate. However, many popular frailty screening methods have not been validated in patients with CKD. This study evaluates the diagnostic accuracy of several frailty screening methods in patients with CKD G4-5 and those established on haemodialysis (G5D). Methods: Ninety participants with CKD G4-5D were recruited from Nephrology Outpatient Clinics and 2 Haemodialysis Units between December 2016 and December 2017. Frailty was diagnosed using the Fried Frailty Phenotype. The following frailty screening tests were evaluated: Clinical Frailty Scale, PRISMA-7, CKD Frailty Index, CKD FI-LAB, walking speed, hand grip strength and Short Physical Performance Battery. Results: The mean age of participants was 69 years (SD ±13). One-third of participants were dialysis-dependent. Nineteen (21%) patients were categorised as frail, 42 (47%) as pre-frail and 29 (32%) as robust. . Conclusions: Walking speed can be used to accurately screen for frailty in CKD populations. If it is not practical to perform a physical assessment to screen for frailty, the Clinical Frailty Scale is a useful alternative.
Introduction
Frailty is an especially problematic condition associated with ageing, though it is not universally experienced by all older individuals [1] . It is a state of increased vulnerability such that individuals who may otherwise live independently require additional care and support when exposed to an apparently minor physical insult, for example, a simple infection or fall [1] . It is the result of progressive and sustained deterioration of numerous physiological processes, which when accumulated are associated with adverse health outcomes [1] . Many of the pathophysiological processes inherent to chronic kidney disease (CKD) appear to propagate the trajectory from robustness to frailty [2] . The prevalence of frailty increases with worsening kidney function, with a report categorising as many as two-thirds of dialysis-dependent CKD patients as frail [3, 4] . Importantly, frail patients with CKD have worse outcomes than those that are robust with CKD, including an increased falls, hospitalisation and mortality rate [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] .
An international consensus group has advised that frailty screening should be routinely performed in older adults so that targeted management strategies can be offered [13] . Arguably, this is especially important in those with chronic conditions, such as CKD, given the associated predisposition to frailty. Several concepts of frailty have been proposed with varying degrees of physical, psychological and social components. The 2 most popular concepts are the Fried Frailty Phenotype and the deficit accumulation model, also known as the Frailty Index (FI) [14, 15] . Though both have their individual merits, the Frailty Phenotype has a more robust evidence base in terms of predicting outcomes in CKD cohorts [3] . The Frailty Phenotype is a time-consuming evaluation involving a combination of questionnaires and physical assessments (online suppl. Table 1 ; for all online suppl. material, see www.karger.com/doi/10.1159/000494223) [14] . It is therefore not practical to perform this assessment routinely within nephrology outpatient services. Unfortunately, there is poor agreement between nephrologistperceived frailty and this suggested diagnostic criteria for physical frailty [16] . Hence, there is a need for an efficient, sensitive and discriminative outpatient screening method in the CKD population that identifies at-risk individuals likely to have frailty, as defined by an acknowledged operationalised definition of the construct of frailty. Several frailty screening methods have been validated in the general older population [17] . However, many popular frailty screening methods have not been studied in CKD patients. This study evaluates the diagnostic accuracy of several proposed frailty screening methods in patients with CKD stage 4 and 5 (G4-5) and those established on haemodialysis (G5D), using the Frailty Phenotype as the reference standard. A convenience series of participants was recruited from Lancashire Teaching Hospitals NHS Foundation Trust between December 2016 and December 2017 from nephrology outpatient  clinics and 2 Haemodialysis Units. Though there are distinctions between patients that are pre-dialysis and dialysis-dependent, the drivers of frailty are similar, and the clinical expression of frailty is comparable [18] . Therefore, patients ≥18 years old with CKD G4-5 and CKD G5D were eligible for participation in the study. Patients who had a lower limb amputation, metastatic carcinoma, unstable angina or who had a been diagnosed, in the preceding 3 months, with a myocardial infarction, transient ischaemic attack or stroke were excluded from the study. Patients who did not have sufficient understanding of the English language to complete study questionnaires were also excluded. Ethical approval was obtained from the NHS Health Research Authority (IRAS Project ID 216379). Formal written informed consent was obtained for all participants.
Methods

Study Design and Participant Selection
Data Collection and Analyses
Prior to the assessment of index tests, baseline demographic and clinical characteristics data were collected from medical records and during participant interview/assessment. All participants had a Charlson Comorbidity Index score calculated and a Karnofsky Performance Status Scale assessment performed. Participants also completed the Mini-Mental State Examination and the Seniors in the Community: Risk Evaluation for Eating and Nutrition Index [19, 20] .
The following frailty screening methods were assessed: Clinical Frailty Scale, PRISMA-7 questionnaire, CKD FI, CKD FI-LAB, walking speed, hand grip strength and the Short Physical Performance Battery (SPPB) [15, [21] [22] [23] [24] . The Clinical Frailty Scale is a frailty assessment tool that provides 9 descriptors of levels of fitness/frailty (online suppl. Fig. 1 ) [15] . It relies upon a health professional's assessment of an individual's frailty status using the descriptors as guidance. A score of '4' defines individuals as 'vulnerable', whereas a score of '5' considers individuals to be 'mildly frail'. The Clinical Frailty Scale was assessed by a clinician who had access to participant clinical records prior to performing the assessment [15] . The British Geriatrics Society has recommended the PRISMA-7 as a frailty screening tool, with a cut-off of ≥3 used to identify vulnerable individuals (online suppl. Table 2 ) [21, 25] . Participants were asked the questions within the PRISMA-7 questionnaire by a member of the research team. Published recommendations were used to construct a CKD FI and CKD FI-LAB (online suppl. Table 3 , 4, respectively) [22, 23, 26] . Although the FI was not originally intended to be dichotomised, a cut-off of > 0.21 has been suggested in the literature [26] . At least 70% of variables were required to generate a CKD FI-LAB score [23] .
Hand grip strength (Takei 5101 GRIP-D dynamometer, Takei Scientific Inst. Co. Ltd., Niigata, Japan) was assessed in the seated position with the elbow positioned at 90 degrees, supported by the arm of a chair, and the dynamometer supported by the assessor. Both arms were examined with the highest score from 3 efforts from each side being used for analysis [27] . The body mass index and gender stratified hand grip strength cut-offs proposed by the Fried Frailty Phenotype were used to identify frailty [14] . Laure- tani et al. [28] proposed cut-offs of < 30 kg for men and < 20 kg for women for the diagnosis of sarcopenia were also assessed . Walking speed was assessed by asking participants to walk 15 feet (4.57 m) at their normal walking pace on 2 occasions. Participants were advised to use their walking aid, if they normally used one. Infrared timing gates (Brower Timing System 2012, Brower Timing Systems, Draper, UT, USA) were used to record walking time. The fastest of 2 trials was used for analysis. Participants physically unable to complete the assessment were assigned the slowest time within the cohort. The height and gender stratified walking speed cut-offs suggested by the Fried Frailty Phenotype were used to identify frailty [14] . Lauretani et al. [28] proposed cut-off of ≤0.8 m/s for the diagnosis of sarcopenia was also assessed. Finally, the SPPB, a composite measure of lower extremity function, was performed [24, 29] . In addition to an assessment of walking speed as described above, it includes an assessment of balance and time to complete 5 chair stands [24, 29] . A cut-off of 9 has been suggested to identify at-risk individuals [29] .
The Frailty Phenotype was used as the reference standard for all screening tests [14] . It was assessed as originally described by Fried et al. [14] including assessments of unintentional weight loss, weakness (handgrip strength), self-perceived exhaustion, slowness (walking speed) and physical activity (online suppl. Table 1 ). Frailty was diagnosed if 3 or more frailty criteria were present. Prefrailty was defined as the presence of 1 or 2 frailty criteria. The Frailty Phenotype assessment was performed at the same study visit as, and immediately following, index test assessments (except in the case of hand grip strength, walking speed and SPPB assessments, which were performed concurrently to the Frailty Phenotype assessment).
Given that hand grip strength and walking speed were also components of the Frailty Phenotype, a modified version of the Frailty Phenotype was created and used as the reference standard in a sensitivity analysis. Participants completed the RAND 36-Item Health Survey 1.0 and were assigned 2 points if they scored < 75 in the Physical Functioning domain. As described by Johansen et al. [4] , this score replaced the measures of weakness and slowness described in the original Frailty Phenotype. Unintentional weight loss, self-perceived exhaustion and physical activity were assessed as described by Fried et al. [14] (online suppl. Table 1) .
Statistical Analysis
All statistical analyses were performed on IBM SPSS Statistics Software (version 22, IBM Corp) or StatsDirect Statistical Software (version 3.0.167, January 28, 2016). Descriptive statistics were used to summarise demographic data and clinical characteristics. Differences in baseline demographic and clinical characteristic data between non-frail and frail participants were assessed using the Independent t test, Mann-Whitney U test, chisquare test and Fisher's exact test depending upon the type and distribution of the data. Considering type 1 errors associated with multiple comparisons, a Holm-Bonferroni Sequential Correction was applied when comparing baseline demographics and clinical characteristics between groups [30, 31] . The chi-square test for trend was used to assess the differences between the proportion of participants categorised as robust, pre-frail and frail by CKD stage. The correlation between index tests and the Frailty Phenotype was assessed using Spearman's Correlation. Receiver operator characteristic analyses were performed for the screening tests to establish the area under the curve (AUC) and review the sensitivity and specificity of test cut-offs. Additional tests of diagnostic accuracy included: positive predictive value, negative predictive value, positive likelihood ratio and negative likelihood ratio. A p value < 0.05 was considered statistically significant.
Sample Size
The sample size calculation was primarily based on obtaining a 95% CI width for the Spearman correlation coefficient of the Clinical Frailty Scale and Frailty Phenotype scores of no more than 0.17, assuming a true correlation of 0.8. This gave a minimum sample size of 90, using the 2-stage approximation suggested by Bonett and Wright [32] . A sample size of 90 (with an assumed 20 frail and 70 non-frail individuals, defined by the Frailty Phenotype) also enables an estimation of the AUC from a receiver operator characteristic curve analysis to within ±0.1 with 95% confidence assuming a true AUC of 0.9 [33] .
Results
A total of 90 participants completed all assessments (online suppl. Fig. 2 ). The mean age of participants was 69 years (SD ±13) with an equal number of male and female participants. Most participants were White British (n = 87, 97%). One-third of participants were dialysis dependent. Nineteen (21%) patients were categorised as frail, 42 (47%) as pre-frail and 29 (32%) as robust. Study visits were approximately 90 min in duration. Breaks were allowed as needed, though participants did not report suffering any fatigue during visits. No adverse events occurred during assessments. Table 1 demonstrates the demographics and clinical characteristics of non-frail (including robust and prefrail) and frail participants. Frail participants had a lower Karnofsky score (60 vs. 80, p < 0.001) than non-frail participants. Notably, there was no statistically significant difference in age and Charlson Comorbidity Index scores between frail and non-frail participants (73 vs. 68 years [p = 1.00] and 4 vs. 3 [p = 1.00], respectively). There was a higher proportion of dialysis-dependent participants categorised as frail when participants were sub-classified as robust, pre-frail and frail and by CKD stage (CKD G4 11%, CKD G5 20%, CKD G5D 33%, p = 0.01; Fig. 1 ). Table 2 Table 5 demonstrates cross-tabulation of the index test results by Frailty Phenotype frailty diagnosis. Table 3 illustrates the diagnostic accuracy of frailty screening methods in CKD G4-5D categorised by age and dialysis-dependency. The frailty screening methods performed similarly in these sub-groups. Notable exceptions include the PRISMA-7 that had a non-significant AUC value in the < 65 age group, the CKD FI-LAB that had a higher AUC value in the < 65 age group and hand grip strength that had a lower, though still reasonable, AUC value in the dialysis-dependent group.
Frailty Associations
Frailty Screening Methods
Sensitivity Analyses
Using the modified version of the Frailty Phenotype, 47 participants (52%) were categorised as frail. When using this as the reference standard, the AUC value, though attenuated, remained high for all the physical assessments 
Discussion
To our knowledge, although frailty screening methods have been evaluated in CKD populations, this is the first study that evaluates the diagnostic accuracy of the Clinical Frailty Scale, PRISMA-7 and FI-LAB in a pre-dialysis and dialysis dependent CKD population using the Frailty Phenotype as the reference standard [3, [34] [35] [36] [37] . Comparable to other reports, the prevalence of frailty increased with worsening kidney function in this cohort [5, 38, 39] . There was a similar age between non-frail and frail groups, highlighting that frailty is a syndrome that is not merely due to the ageing process. In addition, there was no statistically significant difference in the Charlson Comorbidity Index scores between non-frail and frail participants. This is in accordance with the conclusion made by Fried et al. [14] that comorbidity, though a risk factor, is not synonymous with frailty. Disability is a consequence of frailty; it is therefore unsurprising that within this cohort frail participants had a significantly worse performance status [14] .
Studies have demonstrated a correlation between proinflammatory cytokines and white blood cell count with frailty in older adults [40] [41] [42] [43] . Pro-inflammatory cytokines were not measured directly in our study, though there was no significant difference in other markers of inflammation between the non-frail and frail groups. Furthermore, low vitamin D levels have been associated with frailty in the older adult population [42, 44] . However, there was no significant difference in vitamin D level between non-frail and frail groups in this cohort of CKD patients. These findings may be explained by the pathogenesis of frailty in CKD being distinct from the general older population, with factors such as the accumulation of uraemic toxins, reduced appetite, metabolic acidosis and anabolic hormone dysregulation contributing more prominently [2, 18] . Walking speed, hand grip strength and the SPPB have all been proposed as frailty screening measures [17, 24, 25, 45, 46] . However, poor physical performance of the lower limbs, rather than upper limbs, is most predictive of outcomes in patients with CKD [47] . Roshanravan et al. [47] demonstrated that walking speed is associated with mortality in patients with CKD, unlike hand grip strength. Within our study, walking speed was the superior frailty screening test with excellent equipoise between sensitivity/specificity and positive predicative value/negative predictive value. Though AUC values were attenuated when the physical measures were compared against a modified version of the Frailty Phenotype, they remained high with walking speed again having the best performance. Clegg et al. [17] demonstrated that, in the general older population, walking speed similarly performs well as a frailty screening measure.
Recognising that a frailty screening programme involving detailed physical assessments would be a timedemanding endeavour, several non-physical assessment frailty measures were studied, specifically the Clinical Frailty Scale, PRISMA-7, CKD FI and CKD FI-LAB. The Clinical Frailty Scale had the best performance of these measures in terms of identifying frailty. It also has the most extensive evidence base for predicting outcomes in patients with CKD [15, [48] [49] [50] . Alfaadhel et al. [49] demonstrated that each point increase in the Clinical Frailty Scale score at dialysis initiation was associated with a mortality hazard ratio of 1.22 (95% CI 1.04-1.43). Pugh et al. [50] also showed an association with Clinical Frailty Scale scores and mortality in a group of CKD patients referred for pre-dialysis education (hazard ratio 1.35 [95% CI 1.16-1.57]). Finally, Iyasere et al. [48] demonstrated that higher Clinical Frailty Scale scores are associated with worse health-related quality of life in older patients receiving assisted peritoneal dialysis and haemodialysis. The inter-rater reliability of the Clinical Frailty Scale requires further assessment in this population, including that of non-clinician users.
Though the FI correlates with the Frailty Phenotype in the older population, it has only been validated in a CKD cohort against a modified version of the Frailty Phenotype that substituted objective measurements for self-reported alternatives [37, 51] . In our study, the previously suggested FI cut-off of >0.21 [26] considerably over-estimated the prevalence of frailty and offered poor specificity. A cut-off of > 0.32 provided a better balance between sensitivity and specificity. Physical assessment variables were deliberately not incorporated within the CKD FI. The rationale for doing so was to improve its practicality when used as a frailty screening method, though in its current form, it is still a time-demanding measure. Further study is needed on the prognostic value of the FI in CKD populations and of the feasibility of incorporating such a screening method in nephrology outpatient services. The electronic FI, described by Clegg et al. [52] , may improve the usability of the FI in CKD populations. However, the construct validity of the electronic FI in patients with advanced CKD requires assessment. The FI-LAB, which consists of standard laboratory test result variables and systolic and diastolic blood pressure, has been studied in the older population [23] . It has been shown to correlate with the standard FI and to be predictive of outcomes in the older population [23, 53, 54] . However, the CKD FI-LAB only weakly correlated with the Frailty Phenotype and had a non-significant AUC value in our overall cohort, suggesting that it was not a useful test. This is especially disappointing given the wealth of laboratory variables available for the typical nephrology patient.
The PRISMA-7 correlated moderately with the Frailty Phenotype, compared with the strong correlation for the Clinical Frailty Scale and the CKD FI. Using the suggested cut-off of ≥3, the PRISMA 7 over-estimated the prevalence of frailty, though afforded a reasonable balance between sensitivity and specificity. This short questionnaire could certainly be incorporated into clinical practice, though the Clinical Frailty Scale should be considered in the first instance given its superior diagnostic accuracy.
Notwithstanding the practical usefulness of this study, there are recognised limitations. Although the study's sample size allows an accurate assessment of the screening tests' correlation with the Frailty Phenotype and their respective AUC values, thus providing a valuable measure of their diagnostic accuracy, the precision of the screening tests' sensitivity and specificity would benefit from being examined in a larger sample. Furthermore, our data were obtained from a single-centre, with a predominantly White British population. The high proportion of White British participants recruited to the study may also reflect a necessary exclusion criterion, that is, patients who do not have sufficient understanding of the English language to complete study questionnaires [55] . Ethnicity appears to affect the expression of frailty with studies showing a higher prevalence of frailty in those of Black and Hispanic ethnicity, though it has been reported that frailty is similarly hazardous regardless of ethnicity in those with dialysis-dependent CKD [4, 56, 57] . Further investigation within more culturally diverse cohorts is needed to verify the present results in those cohorts and confirm the generalisability of our results. Finally, the frailty screening methods used in our study were only performed at 1 time point and therefore we cannot report their reliability. Other studies have reported the reliability of physical assessment measures, though the reliability of the Clinical Frailty Scale and PRISMA-7 have not been assessed in an advanced CKD cohort to our knowledge [58] [59] [60] .
Conclusions
Frailty is highly prevalent in CKD with the prevalence increasing with worsening kidney function. Walking speed is a very useful frailty screening measure in patients with advanced CKD, as is the case in the general older population [17] . If it is not practical to perform a physical assessment, a non-physical assessment frailty screening method should be performed. The Clinical Frailty Scale was the most accurate non-physical assessment frailty screening method and currently has the strongest evidence base for prognostication in advanced CKD populations [48] [49] [50] . Further study is needed on the optimum management strategies for frail patients with CKD. Walking speed or a Clinical Frailty Scale assessment could be used to identify physically frail patients for randomised controlled trials of management strategies that aim to improve outcomes of this vulnerable patient group.
